TA214 Breast cancer - bevacizumab (in combination with a taxane): Appendix B proposal paper presented to the Institute's Guidance Executive
|
TA214 Breast cancer - bevacizumab (in combination with a taxane): Appendix B proposal paper presented to the Institute's Guidance Executive
29 July 2013 (229.84 Kb 6 sec) |
This page was last updated: 31 July 2013